Slideshows Images Quizzes

Nasacort AQ

Last reviewed on RxList: 11/16/2016
Nasacort AQ Side Effects Center

Last reviewed on RxList 11/11/2016

Nasacort AQ (triamcinolone acetonide) Nasal Spray is a nasal (for the nose) steroid used to treat sneezing, itching, and runny nose caused by seasonal allergies or hay fever. Nasacort AQ is available in generic form. Common side effects of Nasacort AQ include:

  • nose/throat dryness or irritation,
  • cough,
  • sneezing after use of the medicine,
  • nosebleeds,
  • stinging or burning in your nose,
  • sore throat,
  • stuffy nose,
  • watery eyes,
  • headache,
  • nausea,
  • vomiting, and
  • unpleasant taste/smell.

Tell your doctor if you have rare but serious side effects of Nasacort AQ including:

  • loss of taste or smell, or
  • pain and sores in your nose.

The recommended starting and maximum dose for adults and children 12 and older is 220 mcg per day as two sprays in each nostril once daily. When symptoms are controlled, reducing the dose to 110 mcg per day (one spray in each nostril once a day) can be effective to control symptoms. Pediatric dose for children 2 to 12 is 110 mcg per day given as one spray in each nostril once daily. Nasacort AQ may interact with cancer medicine (chemotherapy), cyclosporine, sirolimus, tacrolimus, basiliximab, efalizumab, muromonab-CD3, mycophenolate mofetil, azathioprine, leflunomide, etanercept, or other steroids. Tell your doctor all medications you use. During pregnancy, Nasacort AQ should be used only when prescribed. Rarely, infants born to mothers who have used corticosteroids (including triamcinolone) for a long time may have low levels of corticosteroid hormone. Tell your doctor if you notice symptoms such as persistent nausea/vomiting, severe diarrhea, or weakness in your newborn. It is unknown if this drug passes into breast milk. Similar drugs pass into breast milk. Consult your doctor before breastfeeding.

Our Nasacort AQ (triamcinolone acetonide) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Nasacort AQ Consumer Information

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have any of these serious side effects:

  • weakness, tired feeling, nausea, loss of appetite, weight loss;
  • fever, chills, body aches, flu symptoms;
  • easy bruising or bleeding, unusual weakness;
  • white patches or sores inside your nose or mouth, or on your lips; or
  • blurred vision, eye pain, or seeing halos around lights.

Less serious side effects may include:

  • stinging, burning, or bleeding in your nose;
  • sneezing after use of the medicine;
  • sore throat, cough, stuffy nose;
  • watery eyes;
  • headache;
  • nausea, vomiting; or
  • an unpleasant taste or smell.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Nasacort AQ (Triamcinolone Acetonide)

Nasacort AQ Professional Information

SIDE EFFECTS

Systemic and local corticosteroid use may result in the following:

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

In placebo-controlled, double-blind, and open-label clinical studies, 1483 adults and children 12 years and older received treatment with NASACORT AQ Nasal Spray. These patients were treated for an average duration of 51 days. In the controlled trials (2-5 weeks duration) from which the following adverse reaction data are derived, 1394 patients were treated with NASACORT AQ Nasal Spray for an average of 19 days. In a long-term, open-label study, 172 patients received treatment for an average duration of 286 days. Adverse reactions from 12 studies in adults and adolescent patients 12 to 17 years of age receiving NASACORT AQ Nasal Spray 27.5 mcg to 440 mcg once daily are summarized in Table 1.

In clinical trials, nasal septum perforation was reported in one adult patient who received NASACORT AQ Nasal Spray.

Table 1 : Adverse drug reactions > 2% and greater than placebo with NASACORT AQ Nasal Spray 220 mcg treatment in studies in adults and adolescents 12 years and older

Adverse reaction Placebo
(N=962)
%
NASACORT AQ 220 mcg
(N=857)
%
Pharyngitis 3.6 5.1
Epistaxis 0.8 2.7
Cough increased 1.5 2.1
Coding dictionary for adverse events is Coding Symbols for Thesaurus of Adverse Reaction Terms (COSTART).

A total of 602 children 6 to 12 years of age were studied in 3 double-blind, placebo-controlled clinical trials. Of these, 172 received 110 mcg/day and 207 received 220 mcg/day of NASACORT AQ Nasal Spray for two, six, or twelve weeks. The longest average durations of treatment for patients receiving 110 mcg/day and 220 mcg/day were 76 days and 80 days, respectively. One percent of patients treated with NASACORT AQ were discontinued due to adverse experiences. No patient receiving 110 mcg/day and one patient receiving 220mcg/day discontinued due to a serious adverse event. A similar adverse reaction profile was observed in pediatric patients 6-12 years of age as compared to adolescents and adults with the exception of epistaxis which occurred in less than 2% of the children studied. Adverse reactions from 2 studies in children 4 to 12 years of age receiving NASACORT AQ Nasal Spray 110 mcg once daily are summarized in Table 2.

Table 2 : Adverse drug reactions > 2% and greater than placebo with NASACORT AQ Nasal Spray 110 mcg treatment in US studies in patients 4 to 12 years of age

Adverse reaction Placebo
(N=202)
%
NASACORT AQ 110 mcg
(N=179)
%
Flu syndrome 7.4 8.9
Cough increased 6.4 8.4
Pharyngitis 6.4 7.8
Bronchitis 1.0 3.4
Dyspepsia 1.0 3.4
Tooth disorder 1.0 3.4
Coding dictionary for adverse events is Coding Symbols for Thesaurus of Adverse Reaction Terms (COSTART).

A total of 474 children 2 to 5 years of age were studied in a 4-week double-blind, placebo-controlled clinical trial. Of these, 236 received 110 mcg/day of NASACORT AQ Nasal Spray for a mean duration of 28 days. No patient discontinued due to a serious adverse event. Adverse reactions from the single placebo-controlled study in children 2 to 5 years of age receiving NASACORT AQ Nasal Spray 110 mcg once daily are summarized in Table 3.

Table 3 : Adverse drug reactions > 2% and greater than placebo with NASACORT AQ Nasal Spray 110 mcg treatment in children 2 to 5 years of age

Adverse reactions Placebo
(N=238)
%
NASACORT AQ 110 mcg
(N=236)
%
Headache 4.2 5.5
Pharyngolaryngeal pain 4.2 5.5
Epistaxis 5.0 5.1
Nasopharyngitis 3.8 5.1
Abdominal upper pain 0.8 4.7
Diarrhea 1.3 3.0
Asthma 2.1 2.5
Rash 1.7 2.5
Excoriation 0.0 2.5
Rhinorrhea 1.7 2.1
Coding dictionary for adverse events is Medical Dictionary for Regulatory Activities terminology (MedDRA) Version 8.1

In the event of accidental overdose, an increased potential for these adverse experiences may be expected, but acute systemic adverse experiences are unlikely [see OVERDOSAGE].

Post-Marketing Experience

In addition to the adverse drug reactions reported during clinical studies and listed above, the following adverse reactions have been identified during post-approval use of NASACORT AQ Nasal Spray. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Reactions that have been reported during post-marketing experience include: nasal discomfort and congestion, sneezing, alterations of taste and smell, nausea, insomnia, dizziness, fatigue, dyspnea, decreased blood cortisol, cataract, glaucoma, increased ocular pressure, pruritus, rash, and hypersensitivity.

Read the entire FDA prescribing information for Nasacort AQ (Triamcinolone Acetonide)

Related Resources for Nasacort AQ

Read the Nasacort AQ User Reviews »

© Nasacort AQ Patient Information is supplied by Cerner Multum, Inc. and Nasacort AQ Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors